Wang, Jun‐Sing;
Lee, I‐Te;
Lee, Wen‐Jane;
Lin, Shi‐Dou;
Su, Shih‐Li;
Tu, Shih‐Te;
Tseng, Yao‐Hsien;
Lin, Shih‐Yi;
Sheu, Wayne Huey‐Herng
Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy : 以单方二甲双胍治疗的2型糖尿病患者的血糖波动与阿卡波糖治疗后的糖化血红蛋白下降呈正相关
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy : 以单方二甲双胍治疗的2型糖尿病患者的血糖波动与阿卡波糖治疗后的糖化血红蛋白下降呈正相关
:
以单方二甲双胍治疗的2型糖尿病患者的血糖波动与阿卡波糖治疗后的糖化血红蛋白下降呈正相关
Contributor:
Wang, Jun‐Sing;
Lee, I‐Te;
Lee, Wen‐Jane;
Lin, Shi‐Dou;
Su, Shih‐Li;
Tu, Shih‐Te;
Tseng, Yao‐Hsien;
Lin, Shih‐Yi;
Sheu, Wayne Huey‐Herng
Published:
Wiley, 2017
Published in:
Journal of Diabetes, 9 (2017) 3, Seite 248-255
Description:
AbstractBackgroundThe aim of the present study was to examine the association between glycemic excursions before treatment and HbA1c reduction after treatment intensification with acarbose or glibenclamide in patients with type 2 diabetes (T2D).MethodsPatients receiving single or dual oral antidiabetic drug treatment with an HbA1c of 7.0–11.0 % (53–97 mmol/mol) were switched to metformin monotherapy (500 mg, t.i.d.) for 8 weeks, followed by randomization to either acarbose (100 mg, t.i.d.) or glibenclamide (5 mg, t.i.d.) as add‐on treatment for 16 weeks. Glycemic excursions were assessed as mean amplitude of glycemic excursions (MAGE) with 72‐h ambulatory continuous glucose monitoring. Treatment efficacy was evaluated as relative HbA1c reduction (%), calculated as (baseline HbA1c – post‐treatment HbA1c)/baseline HbA1c × 100.ResultsFifty patients (mean [±SD] age 53.5 ± 8.2 years, 48 % men, mean baseline HbA1c 8.4 ± 1.2 %) were analyzed. Baseline MAGE was positively correlated with relative HbA1c reduction from baseline in patients treated with acarbose (r = 0.421, P = 0.029) but not glibenclamide (r = 0.052, P = 0.813). Linear regression analysis revealed that the association between baseline MAGE and relative HbA1c reduction from baseline (β = 0.125, P = 0.029) in patients treated with acarbose remained significant after adjustment for several confounders (P < 0.05 for all models).ConclusionsIn patients with T2D on metformin monotherapy, baseline MAGE was positively correlated with relative HbA1c reduction from baseline after treatment with acarbose, but not glibenclamide. These findings highlight the importance of glycemic excursions in individualized treatment for patients with T2D.